4-(4-fluorophenylsulfonyl)-2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepine | 637029-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 4-(4-fluorophenylsulfonyl)-2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepine
• 英文别名: 4-(4-fluorophenylsulfonyl)-2-phenylethyl-2,3,4,5-tetrahydrobenzodiazepine
• CAS: 637029-07-3
• 化学式: C₂₃H₂₃FN₂O₂S
• 分子量: 410.512
• InChiKey: DVDZORRVRNRWJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.44
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.41
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-甲基咪唑-4-甲醛 、 4-(4-fluorophenylsulfonyl)-2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepine 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 4-(4-fluorophenyl)sulfonyl-1-[(2-methyl-1H-imidazol-5-yl)methyl]-2-(2-phenylethyl)-3,5-dihydro-2H-1,4-benzodiazepine
  参考文献：
  名称：

  Benzodiazepine-based selective inhibitors of mitochondrial F 1 F 0 ATP hydrolase

  摘要：

  A series of benzodiazepine-based inhibitors of mitochondrial F1F0 ATP hydrolase were prepared and evaluated for their ability to selectively inhibit the enzyme in the forward direction. Compounds from this series showed excellent potency and selectivity for ATP hydrolase versus ATP synthase, suggesting a potentially beneficial profile useful for the treatment of ischemic heart disease. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.052
• 作为产物：
  描述：

  2-(2-Aminomethyl-phenylamino)-4-phenyl-butyric acid ethyl ester 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 39.0h， 生成 4-(4-fluorophenylsulfonyl)-2-phenethyl-2,3,4,5-tetrahydro[1,4]benzodiazepine
  参考文献：
  名称：

  Benzodiazepine-based selective inhibitors of mitochondrial F 1 F 0 ATP hydrolase

  摘要：

  A series of benzodiazepine-based inhibitors of mitochondrial F1F0 ATP hydrolase were prepared and evaluated for their ability to selectively inhibit the enzyme in the forward direction. Compounds from this series showed excellent potency and selectivity for ATP hydrolase versus ATP synthase, suggesting a potentially beneficial profile useful for the treatment of ischemic heart disease. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.052

文献信息

• Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
  申请人：——

  公开号：US20040009972A1

  公开（公告）日：2004-01-15

  Compounds having the formula (I), 1 are useful as inhibitors of mitochondrial F 1 F 0 ATP hydrolase, wherein R 1 , R 5 and R 7 are optional substituents, R 2 , R 3 and R 4 are hydrogen, alkyl, or substituted alkyl, or comprise a bond to R, T or Y; Z and Y are selected from C(═O), —CO 2 —, —SO 2 —, —CH 2 —, —CH 2 C(═O)—, and —C(═O)C(═O)—, or Z may be absent; R and T are CH 2 —, —C(═O)—, or —CH[(CH 2 ) p (Q)]—, wherein Q is NR 10 R 11 , OR 10 or CN and p is 0, 1 or 2; R 6 is alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl, heterocyclo, or heteroaryl; R 10 and R 11 are hydrogen, alkyl, or substituted alkyl; and r and t are 0 or 1.

  公式（I）的化合物可作为线粒体F1F0ATP水解酶的抑制剂，其中R1、R5和R7为可选取代基，R2、R3和R4为氢、烷基或取代烷基，或包括与R、T或Y之间的键；Z和Y从C(═O)、—CO2—、—SO2—、—CH2—、— C(═O)—和—C(═O)C(═O)—中选择，或者Z可能不存在；R和T为 —、—C(═O)—或—CH[( )p(Q)]—，其中Q为NR10R11、OR10或CN，p为0、1或2；R6为烷基、烯基、取代烷基、取代烯基、芳基、环烷基、杂环烷基或杂环芳基；R10和R11为氢、烷基或取代烷基；r和t为0或1。